A Phase 1/2 interventional study of SPK-8011 in Hemophilia A, sponsored by Spark Therapeutics, Inc.. Completed at 16 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-30.
Sponsored by Spark Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2017, is one of 4 in phase 1/2, and was the 6th registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Japan
Ages 0–17
Hoffmann-La Roche · Sites in United States
Ages 18+ · Men only
Hoffmann-La Roche · Sites in United States, Argentina, Austria and 15 more countries
Ages 12+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 12+
Hoffmann-La Roche · Sites in United States, Canada, Italy and 3 more countries
Ages 2–59 · Men only
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 12 · Phase 4 2
First in 2012; this study’s year is marked. 3 started in 2017.
This study's enrollment of 25 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 58 across the 20 interventional studies, 66 across the 4 observational. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Spark Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Spark Therapeutics, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
1 of the studies in Hemophilia A by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07416526Phase 3Hoffmann-La RocheA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | 2027-09-23 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.
Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the joints, which can cause chronic joint disease and sometime results in death due to the inability of the blood to clot efficiently. This chronic joint disease can have significant physical, psychosocial, and quality-of-life effects, including financial burden. The current standard of care includes the use of factor-based therapies which are given either as prophylaxis or to treat bleeding, as well as new non-factor prophylaxis therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single intravenous (IV) infusion of SPK-8011 5x10\^11 vector genomes per kilogram (vg/kg) body weight.
Genetic: SPK-8011
Participants received a single IV infusion of SPK-8011 1x10\^12 vg/kg.
Genetic: SPK-8011
Participants received a single IV infusion of SPK-8011 2x10\^12 vg/kg.
Genetic: SPK-8011
Participants received a single IV infusion of SPK-8011 1.5x10\^12 vg/kg.
Genetic: SPK-8011
A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as adverse events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE is defined as an AE with an onset date on or following SPK-8011 administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: From date of first dose to Week 52/End of Study (EOS) Visit
Number of Participants Who Received Corticosteroids for Presumed Immune Response
Time frame: Up to Week 52/EOS Visit
Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)
Median peak FVIII activity up to Week 52
Time frame: Up to Week 52/EOS visit
Nominal FVIII Level by OSA at Week 52/EOS
Steady-state FVIII activity measured by median FVIII levels at week 52 by OSA.
Time frame: Up to Week 52/EOS Visit
Spontaneous Bleeds Annualized Bleeding Rate
Time frame: Week 5 up to Week 52/EOS Visit
Total Annualized FVIII Infusion Rate
Time frame: Week 5 up to Week 52/EOS Visit
Time to Achieve Peak FVIII Activity Level
Time frame: Up to Week 52/EOS Visit
Number of Participants With Vector-shedding Confirmed Below Quantifiable Limits (BQL) of SPK-8011-101 in Bodily Fluids
Time frame: Up to Week 52/EOS Visit
Incidence of Immune Response to the BDD-hFVIII Transgene
Time frame: Up to Week 52/EOS Visit
| Milestone | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Started | 2 | 3 | 9 | 11 |
| Received at least 1 dose of study drug | 2 | 3 | 9 | 11 |
| Completed | 2 | 3 | 9 | 11 |
| Not completed | 0 | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as adverse events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE is defined as an AE with an onset date on or following SPK-8011 administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 2 | 3 | 9 | 11 |
| Participants | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Number of Participants Who Received Corticosteroids for Presumed Immune Response | 0 | 2 | 7 | 10 |
Median peak FVIII activity up to Week 52
| percentage of normal activity | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA) | 11.5 (11 to 12) | 20.0 (6 to 24) | 38.7 (7 to 209) | 55.1 (31 to 112) |
Steady-state FVIII activity measured by median FVIII levels at week 52 by OSA.
| percentage of normal activity | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Nominal FVIII Level by OSA at Week 52/EOS | 5.4 (4.7 to 6.1) | 7.8 (3.0 to 13.9) | 8.4 (3.0 to 19.7) | 4.1 (3.0 to 11.9) |
| annualized number of bleeding events | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Spontaneous Bleeds Annualized Bleeding Rate | NA (NA to NA) | 0.3 (0.2 to 0.6) | 0.0 (0.0 to 1.4) | 0.0 (0.0 to 0.7) |
| total annualized FVIII infusions | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Total Annualized FVIII Infusion Rate | 0.3 ± 0.40 | 3.6 ± 3.18 | 7.4 ± 7.93 | 1.6 ± 1.81 |
| days | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Time to Achieve Peak FVIII Activity Level | 279.5 ± 58.69 | 141.0 ± 151.79 | 56.4 ± 19.84 | 54.6 ± 33.74 |
| Participants | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMCs) | 2 | 3 | 9 | 11 |
| Saliva | 2 | 3 | 9 | 10 |
| Semen | 2 | 2 | 8 | 11 |
| Serum | 2 | 3 | 8 | 10 |
| Urine | 2 | 3 | 9 | 10 |
| Participants | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Incidence of Immune Response to the BDD-hFVIII Transgene | 0 | 0 | 0 | 0 |
Collected over From date of first dose up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPK-8011 5x10^11 vg/kg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| SPK-8011 1x10^12 vg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| SPK-8011 2x10^12 vg/kg | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| SPK-8011 1.5x10^12 vg/kg | 0/11 (0%) | 3/11 (27.3%) | 11/11 (100%) |
| Event | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/2 | 1/3 | 0/9 | 0/11 |
| Transaminases IncreasedInvestigations | 0/2 | 0/3 | 1/9 | 0/11 |
| Abdominal Pain UpperGastrointestinal disorders | 0/2 | 0/3 | 0/9 | 1/11 |
| HypersensitivityImmune system disorders | 0/2 | 0/3 | 0/9 | 1/11 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/9 | 1/11 |
| Event | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg |
|---|---|---|---|---|
| Normocytic AnaemiaBlood and lymphatic system disorders | 1/2 | 0/3 | 0/9 | 0/11 |
| ConjunctivitisInfections and infestations | 1/2 | 0/3 | 0/9 | 1/11 |
| Pulpitis DentalInfections and infestations | 1/2 | 0/3 | 0/9 | 0/11 |
| Iron DeficiencyMetabolism and nutrition disorders | 1/2 | 0/3 | 0/9 | 0/11 |
| Alanine Aminotransferase IncreasedInvestigations | 0/2 | 0/3 | 1/9 | 5/11 |
| Transaminases IncreasedInvestigations | 0/2 | 0/3 | 2/9 | 5/11 |
| ConstipationGastrointestinal disorders | 0/2 | 0/3 | 0/9 | 4/11 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/2 | 0/3 | 1/9 | 4/11 |
| HeadacheNervous system disorders | 0/2 | 0/3 | 1/9 | 4/11 |
| InsomniaPsychiatric disorders | 0/2 | 0/3 | 2/9 | 4/11 |
The Full Analysis Set included all participants who received the infusion of SPK-8011.
| Age, Categorical(Participants) | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 9 | 11 | 25 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 2 | 3 | 9 | 11 | 25 |
| Ethnicity (NIH/OMB)(Participants) | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 9 | 11 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SPK-8011 5x10^11 vg/kg | SPK-8011 1x10^12 vg/kg | SPK-8011 2x10^12 vg/kg | SPK-8011 1.5x10^12 vg/kg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 2 |
| White | 2 | 2 | 9 | 10 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2017 to primary completion in Dec 2023, 82 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 82 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.